Drug Type Small molecule drug |
Synonyms- |
Mechanism Akt-1 inhibitors(Serine/threonine-protein kinase AKT inhibitors), Akt-2 inhibitors(Serine/threonine-protein kinase AKT2 inhibitors), Akt-3 inhibitors(Serine/threonine-protein kinase AKT3 inhibitors) + [2] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H16Cl2F2N4O2 |
InChIKeyAXTAPYRUEKNRBA-JTQLQIEISA-N |
CAS Registry1047634-65-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | - | - | |
Endometrial Carcinoma | Phase 2 | - | - | |
Uterine Cervical Cancer | Phase 2 | - | - |
Not Applicable | Metastatic melanoma Adjuvant | 37 | twzmevcrxw(zgdgrrdytr) = jtnwrelzrn eqrqlenxsy (xumaaikrvi, 14.9 - 28.1) | - | 22 Oct 2023 |